Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT03048084 : Seizure Treatment in Glioma
PhasePhase 4
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

- Histologically proven or suspected diffuse astrocytoma (Isocytrate Dehydrogenase-1
(IDH-1) wildtype or IDH-1 mutated), diffuse oligodendroglioma (IDH-1 mutated and
1p/19q co-deleted), anaplastic astrocytoma (IDH-1 wildtype or IDH-1 mutated),
anaplastic oligodendroglioma (IDH-1 mutated and 1p/19q co-deleted), glioblastoma
(IDH-1 wild-type or IDH-1 mutated), or diffuse astrocytoma not otherwise specified
(NOS), anaplastic astrocytoma NOS, oligodendroglioma NOS, oligoastrocytoma NOS,
anaplastic oligoastrocytoma NOS, anaplastic oligodendroglioma NOS or glioblastoma NOS.

- Adult patients: =18 years of age

- First epileptic seizure, no longer than 2 weeks ago

- Monotherapy with antiepileptic drugs is considered most appropriate at the time of

- Willing to provide written informed consent

Exclusion Criteria:

- Previously treated with antiepileptic drugs, except emergency treatment in the past 2

- History of non-brain tumor related epilepsy

- Pregnancy

- Presence of contra-indications for use of levetiracetam or valproic acid
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557